000 01656cam a2200349 a 4500
003 EG-GiCUC
005 20250223030525.0
008 111207s2011 ua d f m 000 0 eng d
040 _aEG-GiCUC
_beng
_cEG-GiCUC
041 0 _aeng
049 _aDeposite
097 _aPh.D
099 _aCai01.19.04.Ph.D.2011.Ol.A
100 0 _aOla Mohamad Elfarargy
245 1 0 _aAssessment of bisphosphonates use as adjuvant therapy in breast cancer /
_cOla Mohamad Elfarargy ; Supervised Zekri Khalid Zekri , Nadia Iskandar Zakhary , Heba M. Rabie Elzawahry
246 1 5 _aتقييم استخدام عقار البيسفسفونات كعلاج تحفظى فى حالات سرطان الثدى
260 _aCairo :
_bOla Mohamad Elfarargy ,
_c2011
300 _a168 P. :
_bcharts ;
_c25cm
502 _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
520 _aBreast cancer is the most common cancer in female worldwide and considered commonest cause of cancer related death in female. Inspite of an increasing incidence, breast cancer mortality has been declining. This is the combined result of better education, widespread screening programs and more efficacious adjuvant treatments
530 _aIssued also as CD
653 4 _aAdjuvant therapy
653 4 _aBisphosphonates
653 4 _aBreast cancer
700 0 _aHeba Mohamed Rabie Elzawahry ,
_eSupervisor
700 0 _aNadia Iskandar Zakhary ,
_eSupervisor
700 0 _aZekri Khalid Zekri ,
_eSupervisor
856 _uhttp://172.23.153.220/th.pdf
905 _aNazla
_eRevisor
905 _aSamia
_eCataloger
942 _2ddc
_cTH
999 _c36516
_d36516